Senior Scientist, Computational Biology - Drug Discovery

Eikon Therapeutics; Millbrae (CA); On-site; USD 191,000 - 231,000; Full time

Benefits offered by this job

401k with company match

Medical/dental/vision coverage (prem/σ

Mental health benefits

Paid time off and holidays

Life/AD&D insurance

Parental leave

Job summary

Eikon Therapeutics in Millbrae, CA is seeking a Senior Scientist II in Computational Biology to lead early drug discovery with quantitative modeling and cross-functional collaboration. You will apply advanced statistics to high-dimensional data, drive experimental strategies, and collaborate with teams designing new experimental systems.

The role emphasizes deep biological reasoning, methodological creativity, and strong communication to advance proprietary discovery platforms and real-world

Qualifications

• PhD or postdoc with strong quantitative training and 7+ years industry experience.
• Proven record in high-impact, peer-reviewed research.
• Experience applying statistics and methods to biology data.

Responsibilities

• Drive development of novel experimental systems and techniques.
• Develop analytical approaches and proof-of-concept tools.
• Analyze multimodal data to extract insights and define interpretation limits.
• Collaborate with computational and experimental teams to ground models in biology

Skills

Bioinformatics

Industry experience

Multi-modal data

Genomics analyses

Python/R

Public datasets

Publications

Education

PhD or Postdoc + 7y industry

Tools

Python/R

Cloud computing

Containerization

Git version control

Job description

Eikon Therapeutics in Millbrae, CA is seeking a Senior Scientist II in Computational Biology to lead early drug discovery with quantitative modeling and cross-functional collaboration. You will apply advanced statistics to high-dimensional data, drive experimental strategies, and collaborate with teams designing new experimental systems.

The role emphasizes deep biological reasoning, methodological creativity, and strong communication to advance proprietary discovery platforms and real-world